Literature DB >> 2157774

Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans.

P D Smith1, C L Lamerson, S M Banks, S S Saini, L M Wahl, R A Calderone, S M Wahl.   

Abstract

The ability of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) to augment the fungicidal activity of human monocytes for Candida albicans was evaluated. Purified human monocytes cultured with [3H]leucine-labeled C. albicans caused a dose-dependent release of the [3H]leucine. The amount of [3H]leucine released correlated with a decrease in the number of viable yeast colonies. Monocyte cytotoxicity for C. albicans was reduced by superoxide dismutase and catalase and by inhibitors of myeloperoxidase and scavengers of hydroxyl radical and single oxygen, consistent with monocyte candidacidal activity being partly dependent upon products of oxidative metabolism. Monocytes incubated with rhGM-CSF produced more superoxide anion (O2-) spontaneously and after stimulation than control monocytes (P less than .05). Enhanced O2- production was dose-dependent and specific for rhGM-CSF and could be inhibited by antibody to rhGM-CSF. In association with rhGM-CSF-induced production of O2-, the cytokine enhanced cytotoxic activity for C. albicans. These findings indicate that rhGM-CSF stimulates human monocyte fungicidal activity for C. albicans.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157774     DOI: 10.1093/infdis/161.5.999

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Effect of cytokines on anticryptococcal activity of human microglial cells.

Authors:  M M Lipovsky; A E Juliana; G Gekker; S Hu; A I Hoepelman; P K Peterson
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

2.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 3.  Macrophages in resistance to candidiasis.

Authors:  A Vázquez-Torres; E Balish
Journal:  Microbiol Mol Biol Rev       Date:  1997-06       Impact factor: 11.056

Review 4.  Granulocyte-macrophage colony-stimulating factor and the immune system.

Authors:  P E Tarr
Journal:  Med Oncol       Date:  1996-09       Impact factor: 3.064

Review 5.  The potential role of granulocyte-macrophage colony stimulating factor in therapy of fungal infections: a commentary.

Authors:  G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-05       Impact factor: 3.267

6.  Enhanced killing of Candida albicans by human macrophages adherent to type 1 collagen matrices via induction of phagolysosomal fusion.

Authors:  Simon L Newman; Bindu Bhugra; Angela Holly; Randal E Morris
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

7.  Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis.

Authors:  R Badaró; C Nascimento; J S Carvalho; F Badaró; D Russo; J L Ho; S G Reed; W D Johnson; T C Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

8.  Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanism.

Authors:  U E Mai; G I Perez-Perez; L M Wahl; S M Wahl; M J Blaser; P D Smith
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

9.  Enhancement of susceptibility of CB-17 mice to systemic candidiasis by poly(I . C)-induced interferon.

Authors:  J Jensen; E Balish
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

Review 10.  The use of GM-CSF in AIDS.

Authors:  D T Scadden
Journal:  Infection       Date:  1992       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.